Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01291888 · ClinicalTrials.gov registry record

Nebivolol Versus Sustained Release Metoprolol Succinate in Patients With Chronic Kidney Disease

A clinical trial, sponsored by University of Michigan.

Completed
Registry status
50
Enrollment target

NCT01291888 is a clinical trial that has completed, run by University of Michigan. The registered enrollment target is 50 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01291888 has completed, sponsored by University of Michigan.

COMPLETED
Registry status
50 participants
Enrollment target

Study Summary

The investigators postulate that nebivolol will be more effective than an equivalent dose of a comparative BB, specifically sustained release metoprolol succinate, in improving the availability of NO, lowering blood pressure, and reducing albuminuria with implications for slowing progression of CKD and cardiovascular protection in this high risk population. The objective of this proposal is to conduct a randomized pilot clinical trial to determine the relative efficacy and tolerability of nebivolol versus sustained release metoprolol succinate in improving blood pressure in patients with CKD and albuminuria. The primary endpoint would be a decrease in asymmetric dimethyl arginine (ADMA). Secondary endpoints would include a reduction in blood pressure, urinary F2-isoprostanes and albuminuria.

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2011-03
Est. Completion 2014-01

Sponsor

University of Michigan

1,327 total trials

What the Registry Record Tells You About NCT01291888

The ClinicalTrials.gov registry entry for NCT01291888 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT01291888 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01291888 about?

NCT01291888 is a clinical study titled "Nebivolol Versus Sustained Release Metoprolol Succinate in Patients With Chronic Kidney Disease". The investigators postulate that nebivolol will be more effective than an equivalent dose of a comparative BB, specifically sustained release metoprolol succinate, in improving the availability of NO, lowering blood pressure, and reducing albuminuria with implications for slowing progression of CKD ...

What is the current status of trial NCT01291888?

This trial is currently completed. The enrollment target is 50 participants. The study started on 2011-03. Estimated completion is 2014-01.

Who is sponsoring clinical trial NCT01291888?

This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.